Novel ACE2-IgG1 fusions with increased activity against SARS-CoV-2
Iwanaga, N.; Cooper, L.; Rong, L.; Beddingfield, B.; Crabtree, J.; Tripp, R. A.; Kolls, J.
Show abstract
SARS-CoV2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. This fusion protein contained a LALA mutation that abrogates Fcr{gamma} binding, but retains FcRN binding to prolong the half-life, as well as achieve therapeutic concentrations in the lung lavage. Interestingly, a mutation in the catalytic domain of ACE2, MDR504, completely abrogated catalytic activity, but significantly increased binding to SARS-CoV2 spike protein in vitro. This feature correlated with more potent viral neutralization in a plaque assay. Parental administration of the protein showed stable serum concentrations with a serum half-life of [~] 145 hours with excellent bioavailability in the epithelial lining fluid of the lung. Prophylactic administration of MDR504 significantly attenuated SARS-CoV2 infection in a murine model. These data support that the MDR504 hACE2-Fc is an excellent candidate for pre or post-exposure prophylaxis or treatment of COVID-19.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 95%
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 94%
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody 94%
Similar papers in this journal
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern 94%
- SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation 94%
- Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19 94%
Similar papers in this journal
- Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies 93%
- Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay 93%
- Characterization of Collaborative Cross mouse founder strain CAST/EiJ as a novel model for lethal COVID-19 92%
Similar papers in this journal
- mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 94%
- Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma 94%
- Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.